Anti-Leukotriene Agents: A New Direction in Asthma Therapy

References

• Boushey H A, Holtzman M J, Shelter J R, Nadel JA. State of the art: Bronchial hyperreactivity. Am Rev Respir Dis 1980; 122: 389–413
   Google Scholar
• Beasley R, Roche W R, Roberts J A, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806–817
   PubMed Web of Science ®Google Scholar
• Samuelsson B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568–575
   PubMed Web of Science ®Google Scholar
• Drazen J M, Austen K F, Lewis R A, Clark D A, Goto G, Marfat A, Corey EL. Comparative airway and vascular activity of leukotriene C-l and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77: 4345–4358
   PubMed Web of Science ®Google Scholar
• Marom Z, Shelhamer J H, Bach M K, Morton D R, Kaliner M. Slow-reacting substances, leukotriene C4 and D4 increase the release of mucus from human airways. Am Rev Respir Dis 1982; 126: 449–451
   PubMed Web of Science ®Google Scholar
• Barnes N C, Piper P J, Costello JF. Comparative actions of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects. Thorax 1984; 39: 500–504
   PubMed Web of Science ®Google Scholar
• Isono T, Koshihara Y, Murota S, Fukada Y, Furukawa S. Measurement of immunoreactive LTC4 in the blood of asthmatic children. Biochem Biophys Res Commun 1985; 130: 486–492
   PubMed Web of Science ®Google Scholar
• Okubo T, Takahashi H, Sumitomo M, Shindoh K, Suzuki S. Plasma levels of leukotriene C4 and D4 during wheezing attack in asthmatic patients. Int Arch Allergy Appl Immunol 1987; 84: 149–155
   PubMedGoogle Scholar
• Proceedings of workshop panel of a WHO meeting. The prevention of allergic diseases. Clin Allergy 1986; 16: l–60, Suppl 1
   Google Scholar
• Sly RM. Changing asthma mortality and sales of inhaled bronchodilators and antiasthmatic drugs. Ann Allergy 1994; 73: 439–443
   PubMedGoogle Scholar
• Sly RM. Changing asthma mortality. Ann Allergy 1994; 73: 259–268
   PubMedGoogle Scholar
• Arrighi HM. US asthma mortality: 1941 to 1989. Ann Allergy Asthma Immunol 1995; 74: 321–326
   PubMed Web of Science ®Google Scholar
• Larsen GL. The late asthmatic response. Chest 1988; 93: 1287–1289
   PubMed Web of Science ®Google Scholar
• O'Byrne P M, Dolovich J, Hargreave FE. State of the art: Late asthmatic responses. Am Rev Respir Dis 1987; 136: 740–751
   PubMed Web of Science ®Google Scholar
• Schleimer R P, MacGlashan DW, Jr, Peters S P, Pinckard R N, Adkinson NF, Jr, Lichtenstein LM. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 1986; 133: 614–617
   PubMed Web of Science ®Google Scholar
• MacGlashan DW, Jr, Schleimer R P, Peters S P, Schulman E S, Adams GK, III, Newball H H, Lichtenstein LM. Gaieration of leukotrienes by purified human lung mast cells. J Clin Invest 1982; 70: 747–751
   PubMed Web of Science ®Google Scholar
• De Monchy J GR, Kauffman H F, Venge P, Koeter G H, Jansen H M, Sluiter H J, De Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis 1985; 181: 373–376
   Google Scholar
• Wegner C D, Gundel R H, Reilly P, Haynes N, Letts L G, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science 1990; 247: 456–459
   PubMed Web of Science ®Google Scholar
• Gleich G J, Flavahan N A, Fujisawa T, Vanhoutte PM. The eosinophil as a mediator of damage to respiratory epithelium: A model for bronchial reactivity. J Allergy Clin Immunol 1988; 81: 776–781
   PubMed Web of Science ®Google Scholar
• Horn R B, Robin E D, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med 1975; 292: 1152–1155
   PubMed Web of Science ®Google Scholar
• Bousquet J, Chanez D, Lacoste J Y, Barneou G, Ghavanian N, Enhander I, Venge P, Ahlstedt S, Sim-ony-Lafontaine J, Godard P, Michel F-B. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033–1039
   PubMed Web of Science ®Google Scholar
• Calhoun W J, Sedgwick J, Busse WW. The role of eosinophils in the pathophysiology of asthma. Ann NY Acad Sci 1991; 629: 62–72
   PubMed Web of Science ®Google Scholar
• Taniguchi N, Mita H, Saito H, Yui Y, Kajita T, Shida T. Increased generation of leukotriene C4 from eosinophils in asthmatic patients. Allergy 1985; 40: 571–573
   PubMed Web of Science ®Google Scholar
• Laitinen L A, Laitinen A, Haahtela T, Vilkka V, Spur B W, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989–990
   PubMed Web of Science ®Google Scholar
• Spada C S, Nieves A L, Krauss AH-P, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leuko Biol 1994; 55: 183–191
   PubMed Web of Science ®Google Scholar
• Robinson D S, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley A M, Corrigan C, Durham S R, Kay AB. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298–304
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Cytokines as mediators of chronic asthma. Am J Respir Crit Care Med 1994; 150: S42–S49
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathology of asthma. J Allergy Clin Immunol 1993; 92: 1–5
   PubMed Web of Science ®Google Scholar
• National Asthma Education Program, Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma. U.S. Department of Health and Human Services, Public Health Service. 1991, National Institutes of Health Publication No. 91–3042
   Google Scholar
• Global Initiative for Asthma. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. NHLBI. January, 1995, Publication No. 95–3659
   Google Scholar
• Rand C S, Wise R A, Nides M, Simmons M S, Bleecker E R, Kusek J W, Li V C, Tashkin DP. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 246: 1559–1564
   Google Scholar
• Rand C S, Nides M, Cowles M K, Wise R A, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. Am J Respir Crit Care Med 1995; 152: 580–588
   PubMed Web of Science ®Google Scholar
• McFadden ER, Jr. The β-agonist controversy revisited. Ann Allergy Asthma Immunol 1995; 75: 173–176
   PubMed Web of Science ®Google Scholar
• Andersson K E, Persson KE. Extrapulmonary effects of theophylline. Eur J Respir Dis 1980; 63: 17–28
   Google Scholar
• Hanania N A, Chapman K R, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98: 196–208
   PubMed Web of Science ®Google Scholar
• Doull I JM, Freezer N J, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995; 151: 1715–1719
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Borgeat P, Hammarsrrom S, Murphy RC. Introduction of a nomenclature: Leukotrienes. Prostaglandins 1979; 17: 785–787
   PubMed Web of Science ®Google Scholar
• Brocklehurst WE. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416–435
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Dahlen S E, Lindgren J A, Ronzer C A, Serhan CN. Leukotrienes and lipoxis: Structures, biosynthesis and biological effects. Science 1987; 237: 1171–1176
   PubMed Web of Science ®Google Scholar
• Rouzer C A, Ford-Hutchinson A W, Morton H E, Gillard JW. MK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 1990; 265: 1436–1442
   PubMed Web of Science ®Google Scholar
• Haeggstrom J Z, Wetterholm A, Shapiro R, Vallee B L, Samuelsson B. Leukotriene A4 hydrolase: A zinc metalloenzyme. Biochem Biophys Res Comnmn 1990; 172: 965–970
   PubMed Web of Science ®Google Scholar
• Nicholson D W, Ali A, Klemba M W, Munday N A, Zamboni R J, Ford-Hutchinson AW. Human leukotriene C4 synthase expression in dimethyl sulfoxide differentiated U937 cells. J Biol Chem 1992; 267: 17849–17857
   PubMed Web of Science ®Google Scholar
• Welsch D J, Creely D P, Mathis K J, Hauser S D, Isakson PC. Molecular cloning and expression of human leukotriene C4 synthase. Adv Prost Throm Leuko Res 1995; 23: 167–169
   PubMedGoogle Scholar
• Lam B K, Owen WF, Jr, Austen K F, Soberman RJ. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem 1989; 264: 12885–12889
   PubMed Web of Science ®Google Scholar
• Lam B K, Gagnon L, Austen K F, Soberman RJ. The mechanism of leukotriene B4 export from human polymorphonuclear leukocytes. J Biol Chem 1990; 265: 13438–13441
   PubMed Web of Science ®Google Scholar
• Verhagen J, Bel E H, Kijne G M, Sterk P J, Bruynzeel P CB, Veldink G A, Vliegenthart J FC. The excretion of leukotriene E4 into urine following inhalation of leukotriene D4 by human individuals. Biochem Biophys Res Commun 1987; 148: 864–868
   PubMed Web of Science ®Google Scholar
• Taylor G W, Taylor I, Black P, Maltby N H, et al. Urinary leukotriene E4 after antigen challenge in acute asthma and allergic rhinitis. Lancet 1989; 1: 584–588
   PubMed Web of Science ®Google Scholar
• Drazen J M, O'Brien J, Sparrow D, Weiss S T, Martins MA. Recovery of leukotriene E4 from the urine of patients with airways obstruction. Am Rev Respir Dis 1992; 346: 104–108
   Google Scholar
• Taylor I K, Taylor G W, Fuller RW. Platelet activating factor (PAF)-induced bromhoconstriction in asthmatics. Role of cysteinyl-leukotrienes. Thorax 1990; 450: 790
   Google Scholar
• Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4 and histamine in athmatics. Am Rev Respir Dis 1992; 346: 96–103
   Google Scholar
• Lam S, Chan H, Le Riche J C, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 83: 711–717
   Google Scholar
• Nicosia S, Capra V, Ragnini D, Giovanazzi S, Mezzetti M, Keppler D, Muller M, Rovati GE. Receptors for cys-leukotrienes in human lung parenchyma: Characterization by computer modelling and photoaffinity labelling of binding sites. Adv Prost Throm Leuko Res 1995; 23: 267–269
   PubMedGoogle Scholar
• Snyder D W, Krell RD. Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea. J Pharmacol Exp Ther 1984; 231: 616–622
   PubMed Web of Science ®Google Scholar
• Buckner C K, Krell R D, Laravuso R B, Coursin D B, Bernstein P R, Will JA. Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4. J Pharmacol Exp Ther 1986; 237: 558–562
   PubMed Web of Science ®Google Scholar
• Drazen J. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann NY Acad Sci 1988; 524: 289–297
   PubMed Web of Science ®Google Scholar
• Rovati G E, Giovanazzi S, Mezzetti M, Nicosia S. Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pliarmacol 1992; 44: 1411–1415
   PubMed Web of Science ®Google Scholar
• Drazen J. Leukotrienes. Asthma and Rhinitis, W W Busse, S T Holgate. Blackwell Scientific Publications, OxfordUK 1995; 838–850
   Google Scholar
• Coleman R A, Eglen R M, Jones R L, Narumiya S, Shimizu T, Smith W L, Dahlen S E, Drazen J M, Gardiner P J, Jackson W T, Jones T R, Krell R D, Nicosia S. Prostanoid and leukotriene receptors: A progress report from the IUPH AR working parties on classification and nomenclature. Adv Prost Throm Leuko Res 1995; 23: 283–285
   PubMedGoogle Scholar
• Ford-Hutchinson A W, Bray M A, Doig M V, Shipley M E, Smith M JH. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286: 264–265
   PubMed Web of Science ®Google Scholar
• Marom Z, Shelhamer J H, Bach M K, Morton D R, Kaliner M. The effects of arachinoids and leukotrienes on the release of mucus from human airways. Chest 1982; 83: 365–370
   Google Scholar
• Cohen N, Yagaloff KA. Recent progress in the development of leukotriene B4 antagonists. Curr Opin Invest Drugs 1994; 3: 13–22
   Google Scholar
• Barnes N C, Piper P J, Costello JF. Hyperresponsiveness of asthmatics to inhaled leukotriene D4. Am Rev Respir Dis 1985; 131: A24
   Google Scholar
• Fuller R W, Black P N, Dollery CT. Effect of the oral leukotriene D4 antagonist LY 171883 on inhaled and intradermal challenge with antigen and LTD4 in atopic subjects. J Allergy Clin Immunol 1989; 83: 939–944
   PubMed Web of Science ®Google Scholar
• Smith L J, Glass M G, Minkwitz MC. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: A concentration-effect study of ICI-204,219. Clin Pharmacol Ther 1993; 54: 430–436
   PubMed Web of Science ®Google Scholar
• Bernstein J A, Greenberger P A, Patterson R, Glass M, Krell R, Thyrum PT. The effect of the oral leukotriene antagonist, ICI-204,219, on leukotriene D4 and histamine-induced cutaneous vascular reactions in man. J Allergy Clin Immunol 1991; 87: 93–98
   PubMed Web of Science ®Google Scholar
• Finnerty J P, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma: Inhibitory effect of ICI 204,219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992; 745: 746–749
   Google Scholar
• Makker H K, Lau L C, Thomson H W, Binks S M, Holgate ST. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 347: 1413–1418
   Google Scholar
• O'Shaughnessy K M, Taylor I K, O'Connor B, O'Connell F, Thomson H, Dollery CT. Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147: 1431–1435
   PubMed Web of Science ®Google Scholar
• Nathan R A, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994; 305: 483–488
   Google Scholar
• Dahlen B, Zerterstrom O, Bjorck T, Dahlen SE. The leukotriene-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994; 7: 324–331
   PubMed Web of Science ®Google Scholar
• Findlay S R, Barden J M, Easley C B, Glass M. Effect of the oral leukotriene antagonist ICI 204,219 on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040–1045
   PubMed Web of Science ®Google Scholar
• Spector S L, Smith L J, Glass M. the Accolate Asthma Trialists Group: Effect of 6 weeks of therapy with oral doses of ICI-204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. J Respir Crit Care Med 1994; 350: 618–623
   Google Scholar
• Donnelly A L, Glass M, Minkwitz M C, Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am I Respir Crit Care Med 1995; 353: 1734–1739
   Google Scholar
• Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y, Yamamoto K, Dohi Y. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150: 254–257
   PubMed Web of Science ®Google Scholar
• Tariguchi Y, Tamura G, Honma M, Aizawa T, Maruyama N, Shirato K, Takishima T. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92: 507–512
   PubMed Web of Science ®Google Scholar
• Grossman J, Bronsky E, Busse W, Montanaro A, Southern L, Tinkelman D, Dubb J, Faiferman I. A multicenter, double-blind, placebo-controlled study to evaluate the safety, tolerability and clinical activity of oral, twice-daily LTA, pranlukast (SB 205312) in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 95: 352
   Web of Science ®Google Scholar
• Reiss T F, Bronsky E, Kemp I, Guerreiro D, Zhang J. MK-0476, a potent and specific leukotriene (LT)D4 receptor antagonist exhibits a dose response in the inhibition of exercise induced bronchoconstriction at the end of a once daily dosing interval. J Invest Med 1995; 43: 275A
   PubMedGoogle Scholar
• Manning P J, Watson R M, Margolskee D J, Williams V C, Schwartz J, O'Byrne P. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 receptor antagonist. N Engl J Med 1990; 323: 1736–1739
   PubMed Web of Science ®Google Scholar
• Hendeles L, Davison D, Blake K, Harman E, Cooper R, Margolskee D. Leukotriene D4 is an important mediator of antigen-induced bronchoconstriction: Attenuation of dual response with MK-571, a specific leukotriene D4 receptor antagonist. J Allergy Clin Immunol 1990; 8: 197
   Google Scholar
• Dahlen B, Margolskee D J, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48: 1205–1210
   PubMed Web of Science ®Google Scholar
• Rasmussen J B, Eriksson L O, Tagari P, Stahl K G, Andersson KE. Reduced nonspecific bronchial reactivity and airway response to antigen in atopic asthmatic patients treated with the inhaled leukotriene D4 antagonist, L648,051. Allergy 1992; 47: 604–609
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Lavins B J, Hanby LA. Effect of treatment with zafirlukast (Accolate) on bronchial hyper-responsiveness in patients with mild-to-moderate asthma. J Allergy Clin Immunol 1996; 97: 250
   Web of Science ®Google Scholar
• Hui K P, Taylor I K, Taylor G W, Rubin P, Kesterson J, Barnes N C, Barnes PJ. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184–189
   PubMed Web of Science ®Google Scholar
• Israel E, Fischer A R, Rosenberg M A, Lilly C M, Callery J C, Shapiro J, Cohn J, Rubin P, Drazen JM. The pivotal role of 5-lipoxygenase products in the reaction of aspirin sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 348: 1447–1451
   Google Scholar
• Israel E, Rubin P, Kemp J P, Grossman J, Pierson W, Siegel S C, Tinkelman D, Murray J J, Busse W, Segal A T, Fish J, Kaiser H B, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059–1066
   PubMed Web of Science ®Google Scholar
• Israel I, Cohn J, Dube L, Drazen J M. Zileuton Clinical Trial Group., Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: A randomized controlled trial. JAMA 1996; 275(12)931–936
   PubMed Web of Science ®Google Scholar
• Kane G C, Pollice M, Kim C-J, Cohn J, Dworski R T, Murray J J, Sheller J R, Fish J E, Peters SP. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996; 97: 646–654
   PubMed Web of Science ®Google Scholar
• Wenzel S E, Trudeau J B, Kaminsky D A, Cohn J, Martin R J, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 352: 897–905
   Google Scholar
• Nasser S MS, Bell G S, Foster S, Spruce K E, MacMillan R, Williams A J, Lee T H, Arm JP. Effect of the5-lipoxy-genase inhibitor ZD 2138 on aspirin-induced asthma. Thorax 1994; 49: 749–756
   PubMed Web of Science ®Google Scholar
• Nasser S MS, Bell G S, Hawksworth R J, Spruce K E, MacMillan R, Williams A J, Lee T H, Arm JP. Effect of the 5-lipoxygenase inhibitor ZD 2138 on allergen-induced early and late asthmatic responses. Thorax 1994; 49: 743–748
   PubMed Web of Science ®Google Scholar
• Meltzer S S, Johns M A, Rechsteiner E A, Jungerwirth S, D'Amico J M, Bleecker ER. Bronchodilatory effects of BAY 1005, a 5-lipoxygenase inhibitor, in mild to moderate asthma. J Allergy Clin Immunol 1994; 93: 294
   Web of Science ®Google Scholar
• Virchow J C, Noller P S, Weibmann K J, Buhl R, Thal-hofer S, Dorow G, Kunkel G, Ukena D, Ulbrich E, Sybrecht G, Matthys H. Multicenter trial of BAY 1005, a new 5-lipoxygenase activating protein (FLAP) inhibitor in the treatment of chronic asthma. Am J Respir Crit Care Med 1995; 151: A377, (4 part 2)
   Google Scholar
• O'Byrne P M, Watson R M, Strong H A, Wyile G. The effect of treatment with a 5-lipoxygenase inhibitor, BAYx 1005 on allergen-induced asthmatic responses in human subjects. Am J Respir Crit Care Med 1994; 149: A532
   Google Scholar
• Friedman B S, Bel E H, Buntinx A, Tanaka W, Han Y-HR, Shingo S, Spector R, Sterk P. Oral leukotriene inhibitor (MK 886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147: 839–844
   PubMedGoogle Scholar
• Diamant Z, Timmers M C, van der Veen H, Friedman B S, De Smet M, Depre M, Hilliard D, Bel E H, Sterk PJ. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95: 42–51
   PubMed Web of Science ®Google Scholar